|
A Non-small Cell Lung Cancer Tissue Microarray to Analyze Protein Expression
|
Z01 CP 010164
|
$210,949
|
Jen, Jin
|
CCR (NCI)
|
|
A program of immune-based treatments for cancer
|
2K24CA093670-06
|
$178,300
|
CARSON, WILLIAM
|
OHIO STATE UNIVERSITY
|
|
A randomized phase II study of erlotinib with or without the anti-IGF-1R monoclon
|
1R21CA135595-01
|
$369,078
|
Camidge, Ross
|
UNIVERSITY OF COLORADO DENVER
|
|
An Untested Approach: Biomarkers for Colon Cancer
|
5R21CA121294-02
|
$145,505
|
MATTA, KHUSHI
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Angiogenesis imaging
|
Z01 BC 010714
|
$440,297
|
Choyke, Peter
|
CCR (NCI)
|
|
Antibody Engineering for Therapy and Diagnosis of Hematologic Malignancies
|
Z01 BC 010647
|
$410,318
|
Rader, Christoph
|
CCR (NCI)
|
|
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors
|
5P01CA043904-17
|
$2,916,216
|
RAUBITSCHEK, ANDREW
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Antibody Therapy of Cancer
|
Z01 BC 010891
|
$41,650
|
Ho, Mitchell
|
CCR (NCI)
|
|
Antigen Specific T Cell tolerance by Anti CD3 Antibodies
|
9R01CA132197-06A2
|
$361,592
|
ANASETTI, CLAUDIO
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Atlanta Regional Community Clinical Oncology Program (ARCCOP)
|
2U10CA045450-22
|
$761,812
|
SEAY, THOMAS
|
ST. JOSEPH'S HOSPITAL
|
|
B7-DC Cross-linking antibody immunotherapy
|
5R21CA130071-02
|
$285,593
|
MARKOVIC, SVETOMIR
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-19
|
$481,201
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Beaumont Community Clinical Oncology Program
|
5U10CA095860-07
|
$1,049,588
|
DECKER, DAVID
|
WILLIAM BEAUMONT HOSPITAL RESEARCH INST
|
|
Biologic Therapy for B-cell non-Hodgkin's Lymphoma
|
2R01CA092104-05A2
|
$258,741
|
ANSELL, STEPHEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Biological Basis of Breast Density and Cancer Risk
|
5P01CA107584-03
|
$1,299,401
|
TLSTY, THEA
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
|
5R01CA115755-03
|
$319,025
|
SHARKEY, ROBERT
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
Bispecific Antibody Pretargeting for Therapy
|
5R01CA107088-03
|
$512,569
|
SHARKEY, ROBERT
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
Bone Marrow Grafting for Leukemia and Lymphoma
|
5P01CA049605-20
|
$3,446,067
|
NEGRIN, ROBERT
|
STANFORD UNIVERSITY
|
|
Cancer Research for the Ozarks
|
5U10CA045560-20
|
$681,391
|
CAROLLA, ROBERT
|
OZARK HEALTH VENTURES, LLC
|
|
CCOP Research Base, PCPT/PCPT LTFU, and SELECT Programs
|
3U10CA037429-24S1
|
$464,405
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
CCOP Research Base, PCPT/PCPT LTFU, and SELECT Programs
|
7U10CA037429-24
|
$16,768,272
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
CD 74 Directed Immunotherapy for B Cell Malignancies
|
5R21CA126060-02
|
$327,262
|
LEONARD, JOHN
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
|
CD137 Antibody for Cancer Therapy
|
5R01CA106861-06
|
$317,808
|
Chen, Lieping
|
JOHNS HOPKINS UNIVERSITY
|
|
CD20 DNA VACCINATION FOR B-CELL LYMPHOMA
|
5K08CA118260-03
|
$134,622
|
Palomba, MARIA
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Central Illinois Community Clinical Oncology Program
|
5U10CA045807-23
|
$1,053,633
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Cetuximab for Treatment of High-risk Pre-malignant Upper Aerodigestive Lesions
|
1R21CA126055-01A1
|
$369,000
|
CALIFANO, JOSEPH
|
JOHNS HOPKINS UNIVERSITY
|
|
Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia
|
5R01CA111953-03
|
$101,766
|
KAY, NEIL
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
5P01CA081534-09
|
$3,860,269
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
City of Hope Lymphoma SPORE
|
5P50CA107399-05
|
$2,163,322
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-21
|
$315,196
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Clinical Development of Hu14.18-IL2 Targeted Therapy
|
5R01CA032685-24
|
$308,597
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
|
COLUMBIA RIVER ONCOLOGY PROGRAM
|
5U10CA045377-22
|
$745,543
|
LANIER, KEITH
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
Columbus Community Clinical Oncology Program
|
5U10CA035261-25
|
$874,908
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Combination of targeted radiotherapy and anti-angiogenesis for resistant neurobla
|
1R21CA132474-01
|
$420,750
|
MODAK, SHAKEEL
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Combination Therapy in B-Chronic Lymphocytic Leukemia
|
2R01CA095241-06A1
|
$597,549
|
KAY, NEIL
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Community Clinical Oncology Program
|
5U10CA035431-25
|
$1,923,566
|
DAKHIL, SHAKER
|
VIA CHRISTI REGIONAL MEDICAL CENTER
|
|
Consortium Therapeutic Studies of Primary Central Nervous System Malignancies
|
5U01CA105695-05
|
$146,647
|
CLOUGHESY, TIMOTHY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Control of Protein Translation in Cancer Pathogenesis
|
7U01CA084292-10
|
$697,531
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Dayton Clinical Oncology Program
|
5U10CA035090-26
|
$955,207
|
Gross, Howard
|
DAYTON CLINICAL ONCOLOGY PROGRAM
|
|
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer
|
5R01CA123197-02
|
$439,913
|
ZHOU, TONG
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Developing Immune Based Therapies
|
Z01 BC 011072
|
$514,753
|
Mackall, Crystal
|
CCR (NCI)
|
|
Development of Recombinant Toxins to Treat Hematologic Malignancies
|
Z01 BC 010301
|
$558,572
|
Kreitman, Robert
|
CCR (NCI)
|
|
Development of TGF-beta antagonists for cancer therapy
|
Z01 BC 010881
|
$377,752
|
Wakefield, Lalage
|
CCR (NCI)
|
|
DF/HCC Renal Cancer SPORE
|
3P50CA101942-05S1
|
$1,165,299
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Discovery of Drugs, Targets, and Target Strategies for Immunotherapy of CLL
|
Z01 BC 010648
|
$410,318
|
Rader, Christoph
|
CCR (NCI)
|
|
DNA Methylation & Chromatin Modifications: Mechanisms & Applications in Cancer*
|
5P01CA101956-03
|
$2,271,783
|
JACOB, SAMSON
|
OHIO STATE UNIVERSITY
|
|
Duluth Community Clinical Oncology Program
|
5U10CA035269-25
|
$798,586
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
Early prediction of response to combined modality therapy by functional imaging
|
5R21CA123909-02
|
$255,450
|
SARKARIA, JANN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas
|
1R21CA132891-01
|
$210,600
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer
|
1R21CA130241-01A1
|
$330,678
|
ARGIRIS, ATHANASSIOS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|